Related Experiment Videos
[Radiotherapy for non-small cell lung cancer]
Nihon Geka Gakkai Zasshi
|January 1, 1997
Summary
Standard radiotherapy for non-small cell lung cancer showed poor outcomes. Combination chemoradiotherapy, including cisplatin, significantly improves survival rates and reduces metastasis for lung cancer patients.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Oncology
Context:
- Standard radiotherapy for unresectable localized non-small cell lung cancer (NSCLC) has historically yielded unsatisfactory results.
- High incidences of distant metastasis and poor local control necessitate improved therapeutic strategies for NSCLC.
Purpose:
- To review advancements in radiotherapy techniques and chemotherapy combinations for unresectable localized non-small cell lung cancer.
- To evaluate the efficacy of different treatment modalities, including 3D planning, particle radiotherapy, and chemoradiotherapy, in improving patient outcomes.
Summary:
- Prospective randomized clinical trials since the 1970s have explored radiation field encompassing, total dose escalation (up to 70Gy+), and altered fractionation (accelerated hyperfractionation).
- Modern techniques like 3D treatment planning, particle radiotherapy, and brachytherapy are being investigated for more focused treatment.
- Meta-analysis of 11 RCTs indicates that combination chemoradiotherapy with cisplatin significantly enhances median survival time (MST) and the 2-year survival rate in NSCLC patients.
Impact:
- The findings support the integration of chemotherapy with radiotherapy as a superior treatment paradigm for unresectable localized NSCLC.
- This research guides future clinical trial designs and treatment protocols, aiming to further optimize survival and local control for lung cancer patients.